Correlation Between Immix Biopharma and Celularity

Can any of the company-specific risk be diversified away by investing in both Immix Biopharma and Celularity at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Immix Biopharma and Celularity into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Immix Biopharma and Celularity, you can compare the effects of market volatilities on Immix Biopharma and Celularity and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Immix Biopharma with a short position of Celularity. Check out your portfolio center. Please also check ongoing floating volatility patterns of Immix Biopharma and Celularity.

Diversification Opportunities for Immix Biopharma and Celularity

0.81

Correlation Coefficient

Immix Biopharma  Celularity

Very poor diversification

The 3 months correlation between Immix and Celularity is 0.81. Overlapping area represents the amount of risk that can be diversified away by holding Immix Biopharma and Celularity in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Celularity and Immix Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Immix Biopharma are associated (or correlated) with Celularity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Celularity has no effect on the direction of Immix Biopharma i.e., Immix Biopharma and Celularity go up and down completely randomly.

Pair Corralation between Immix Biopharma and Celularity

Given the investment horizon of 90 days Immix Biopharma is expected to under-perform the Celularity. But the stock apears to be less risky and, when comparing its historical volatility, Immix Biopharma is 1.94 times less risky than Celularity. The stock trades about -0.11 of its potential returns per unit of risk. The Celularity is currently generating about 0.01 of returns per unit of risk over similar time horizon. If you would invest  205.00  in Celularity on December 30, 2024 and sell it today you would lose (28.00) from holding Celularity or give up 13.66% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Strong
Accuracy	100.0%
Values	Daily Returns

Immix Biopharma  vs.  Celularity

Immix Biopharma

Risk-Adjusted Performance

Very Weak

Over the last 90 days Immix Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's primary indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Celularity

Risk-Adjusted Performance

Very Weak

Over the last 90 days Celularity has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable essential indicators, Celularity is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors.

Pair Trading with Immix Biopharma and Celularity

The main advantage of trading using opposite Immix Biopharma and Celularity positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Immix Biopharma position performs unexpectedly, Celularity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Celularity will offset losses from the drop in Celularity's long position.

The idea behind Immix Biopharma and Celularity pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.